Getinge AB/Skr GETI B
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Getinge AB
Getinge AB is a Swedish company that specializes in providing products and solutions for healthcare and life sciences. The company’s core business includes the development and manufacturing of equipment and systems for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing, and life science operations. Founded in 1904, Getinge is headquartered in Gothenburg, Sweden, and operates globally with a presence in numerous countries. The company's strategic positioning is strengthened by its focus on innovation and comprehensive solutions that address the complex challenges of medical and pharmaceutical processes, aiming to enhance patient outcomes and operational efficiency.
- Ticker
- Skr GETI B
- Sector
- Health
- Primary listing
- XSTO
- Employees
- 11,847
- Headquarters
- Gothenburg, Sweden
- Website
- www.getinge.com
Getinge AB Metrics
BasicAdvanced
kr 76B
26.99
kr 10.39
0.82
kr 4.75
1.69%
Price and volume
Market cap
kr 76B
Beta
0.82
52-week high
kr 280.70
52-week low
kr 175.90
Average daily volume
549K
Dividend rate
kr 4.75
Financial strength
Current ratio
1.245
Quick ratio
0.718
Long term debt to equity
0.245
Total debt to equity
0.343
Dividend payout ratio (TTM)
45.69%
Interest coverage (TTM)
9.77%
Profitability
EBITDA (TTM)
6,049
Gross margin (TTM)
49.01%
Net profit margin (TTM)
8.21%
Operating margin (TTM)
14.29%
Effective tax rate (TTM)
27.38%
Revenue per employee (TTM)
kr 2,910,000
Management effectiveness
Return on assets (TTM)
5.29%
Return on equity (TTM)
9.14%
Valuation
Price to earnings (TTM)
26.987
Price to revenue (TTM)
2.217
Price to book
2.32
Price to tangible book (TTM)
-20.32
Price to free cash flow (TTM)
17.675
Free cash flow yield (TTM)
5.66%
Free cash flow per share (TTM)
15.864
Dividend yield (TTM)
1.69%
Forward dividend yield
1.69%
Growth
Revenue change (TTM)
-3.90%
Earnings per share change (TTM)
37.78%
3-year revenue growth (CAGR)
4.24%
10-year revenue growth (CAGR)
1.51%
3-year earnings per share growth (CAGR)
7.93%
10-year earnings per share growth (CAGR)
7.49%
3-year dividend per share growth (CAGR)
3.78%
10-year dividend per share growth (CAGR)
5.43%
What the Analysts think about Getinge AB
Analyst ratings (Buy, Hold, Sell) for Getinge AB stock.
Analyst projections of the future price of Getinge AB stock.
Bulls say / Bears say
Underlying margin gains look increasingly real: Q3 adjusted EBITA margin rose to 15.1%, or 14.3% excluding tariff refunds and currency effects, with pricing, product mix and productivity supporting the improvement. (Getinge)
Orders rose 2.6% organically in Q3 and Getinge kept its 2026 organic sales growth guidance at 3–5%. Acute Care Therapies and Surgical Workflows were the main sources of sales growth. (Getinge)
New products offer scope for growth in critical care: Getinge began launching its next-generation Cardiohelp II platform in CE countries and Hong Kong, and received US clearance for a neonatal Edi catheter. (Getinge)
Life Science remains a weak spot: sales in the washer, isolator and steriliser category fell as pharma customers continued to delay investment in capital equipment. (Getinge)
Some of Q3’s reported margin improvement came from tariff refunds and favourable currency effects, which may not recur; management also cited ongoing tariff and geopolitical uncertainty. (Getinge)
Product-quality risk has not disappeared: the FDA lists an open Class II recall of Getinge PVC thoracic catheters after bacterial endotoxin testing produced an out-of-specification result. (US Food and Drug Administration)
Data summarised monthly by Lightyear AI. Last updated on 22 Oct 2026.
Getinge AB Financial Performance
Revenues and expenses
Getinge AB Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Getinge AB
AllUSDEUR
Fund name | Fund size | Skr GETI B weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.36% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.36% |
iShares STOXX Europe 600 Health Care€EXV4 | €709M | 0.30% |
iShares MSCI World Small Cap£WLDS | $9B | 0.05% |
iShares MSCI World Small Cap€IUSN | $9B | 0.05% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.